Afya Limited (Nasdaq: AFYA) (“Afya” or the
“Company”), the leading medical education group and digital health
service provider in Brazil, reported today financial and operating
results for the three and twelve-month periods ended December 31,
2020 (fourth quarter 2020 and full year 2020, respectively).
Financial results are expressed in Brazilian Reais and are
presented in accordance with International Financial Reporting
Standards (IFRS).
Full Year 2020 Highlights
- FY20 Adjusted
Net Revenue of R$1,207.7 million, up 60.9% YoY. Excluding
acquisitions FY20 Adjusted Net Revenue increased 27.6% YoY reaching
R$957.8 million.
- 2020 Adjusted
EBITDA increased 68.9% YoY reaching R$563.1 million, with an
Adjusted EBITDA Margin of 46.6%, increasing 220 basis points (bps).
Adjusted EBITDA excluding acquisitions increased 40.1% YoY,
reaching R$467.2 million, with Adjusted EBITDA Margin of 48.8%, 440
basis points higher than the same period of 2019.
- FY20 Adjusted
Net Income of R$390.9 million was 72.2% higher than FY19.
- Cash conversion
of 75.7% with a solid cash position of R$1.0 billion at
year-end.
- 2,143 medical
seats, 36.3% increase YoY and 11,030 medical students, which was
67.2% up.
Fourth Quarter 2020
Highlights
- 4Q20 Adjusted
Net Revenue increased 57.5% YoY to R$347.9 million. Adjusted Net
Revenue excluding acquisitions grew 10.7%, reaching R$244.4
million.
- 4Q20 Adjusted
EBITDA increased 51.3% YoY reaching R$155.0 million and Adjusted
EBITDA Margin of 44.6%. Adjusted EBITDA excluding acquisitions grew
8.1% reaching R$ 110.8 million, with Adjusted EBITDA Margin of
45.3%.
- 4Q20 Adjusted
Net Income of R$83.1 million, 14.6% higher than 4Q19.
Table 1: Financial
Highlights |
|
For the three months period ended December
31, |
|
For the twelve months period ended December
31, |
(in thousand of R$) |
2020 |
2020 Ex Acquisitions* |
2019 |
% Chg |
% Chg Ex Acquisitions |
|
2020 |
2020 Ex Acquisitions* |
2019 |
% Chg |
% Chg Ex Acquisitions |
(a) Net Revenue |
345,266 |
243,795 |
220,846 |
56.3% |
10.4% |
|
1,201,191 |
954,839 |
750,630 |
60.0% |
27.2% |
(b) Adjusted Net Revenue (3) |
347,896 |
244,405 |
220,846 |
57.5% |
10.7% |
|
1,207,735 |
957,790 |
750,630 |
60.9% |
27.6% |
(c) Pro forma Adjusted Net Revenue (1) |
347,896 |
244,405 |
220,846 |
57.5% |
10.7% |
|
1,207,735 |
957,790 |
829,731 |
45.6% |
15.4% |
(d) Adjusted EBITDA (2) |
155,048 |
110,746 |
102,491 |
51.3% |
8.1% |
|
563,113 |
467,235 |
333,436 |
68.9% |
40.1% |
(e) = (d)/(b) Adjusted EBITDA Margin |
44.6% |
45.3% |
46.4% |
-180 bps |
-110 bps |
|
46.6% |
48.8% |
44.4% |
220 bps |
440 bps |
(f) Pro forma Adjusted EBITDA (1) |
155,048 |
110,746 |
102,491 |
51.3% |
8.1% |
|
563,113 |
467,235 |
361,622 |
55.7% |
29.2% |
(g) = (e)/(c) Pro forma Adjusted EBITDA Margin (1) |
44.6% |
45.3% |
46.4% |
-180 bps |
-110 bps |
|
46.6% |
48.8% |
43.6% |
300 bps |
520 bps |
(h) Adjusted Net Income |
83,116 |
49,907 |
72,529 |
14.6% |
-31.2% |
|
390,909 |
322,029 |
226,953 |
72.2% |
41.9% |
|
|
|
|
|
|
|
|
|
|
|
|
* Acquisitions includes UniRedentor, UniSL, PEBMED, FCMPB,
MedPhone, FESAR and ITPAC Santa Inês. |
1. Includes the pro-forma results of Medcel, IPEMED and FASA, as if
the acquisition had been consummated on January 1, 2019. |
2. See more information on "Non-GAAP Financial Measures" (Item
10). |
3. Includes mandatory discounts in tuition fees granted by state
decrees and individual and collective legal proceedings due COVID
19 on site classes restriction. |
1. Message from
Management
Virgilio Gibbon, Afya’s CEO,
stated:
I am extremely proud that Afya has
over-delivered outstanding results since the IPO. Our performance
reflects successful execution of our assertive strategy, commitment
of our team members and the resilience of our business model,
particularly during a year of a worldwide pandemic. Since 2017, our
Net Revenue has grown almost 6 times and we are not only growing
fast, our Adjusted Ebitda has grown almost 8 times and increased
1,300 basis points in margin in the same period. And there is more:
Afya generated operating cash of R$391 million in 2020, 9x higher
than 2017’s, reaffirming our tripod of strong growth with high
profitability and cash generation while reinforcing our financial
strength to continue consolidating medical seats, even after we
achieve the 1,000 seats guided in the IPO.
Along with this impressive growth and
profitability figures, we have been creating the largest medical
ecosystem in Brazil, with more than 198 thousand physicians and
medical students using one of our products. We also have more than
430 partnerships with hospitals and clinics in Brazil. Afya’s focus
continues to be providing a lifelong learning experience for
physicians and to help doctors to transform the Brazilian
healthcare environment.
During the year, we successfully executed our
strategy to continue to be the market leader of medical school
seats in Brazil. We have completed 9 acquisitions since we became
public, adding 851 medical seats in less than two years, or
approximately 85% of our three-year target shared during our IPO.
Importantly, we have a solid track record of integrating acquired
companies and delivering cost efficiencies and synergies that can
be seen in the margin expansion we are presenting. These
acquisitions set us up to deliver continued strong results in the
months and years to come. Our medical education business remains,
and will continue to be, the cornerstone of our business in the
short and midterms. We have become extremely efficient at operating
medical schools and we continue to see opportunities in this
area.
In the beginning of the year, due to the
pandemic, we had to adapt with the agility needed to stay focused
on providing the high-quality educational experience that our
students had come to expect from us while at the same time
executing on our long-term strategic plan. We are fortunate that,
as a business, we are able to assist the medical community by using
our campuses as health centers and by providing free courses to
assist hospitals, medical schools, physicians and nurses at this
difficult times.
The COVID-19 pandemic intensified some behavior
shifts already underway. It has caused the acceleration of our long
term plan as well as the unfolding of our digital services
strategy. As evidenced by the pandemic, the medical community and
patients have embraced a digital component to healthcare. We
discussed in the past that digital assets were appealing to us so
that we can add more services to medical students and
professionals, thus maximizing our product offering and lifetime
customer value. In turn, during the year, we furthered Afya’s
Digital Strategy with the acquisition of PEBMED, iClinic, MedPhone
and Medical Harbour. These acquisitions enable us to deepen our
relationship with our students as well as put our brand in front of
many new doctors, nurses and other medical personnel and students,
enhancing our competitive position and our capabilities.
We continue to have a peer-leading capital
structure, providing us with the ability to adapt to the dynamic
environment and maintain our focus on long-term value generation.
Given our strong free cash flow and liquidity, we remain committed
to our long-term capital priorities, with a balanced approach to
invest in the business and return cash to our shareholders, all
while keeping our students, faculty members and employees safe and
managing through this volatile environment.
Our quality and execution was also acknowledged
and rewarded this year. Afya was the winner of the Education sector
in the Época Negócios 360 survey and also won the Golden Tombstone
in the Equity category. This award is evaluated by the Brazilian
Institute of Finance Executives (IBEF – São Paulo Chapter) and
recognizes Equity Operations in aspects such as complexity of the
transaction, innovation, pricing and others.
Lastly but very important, beginning with this
earnings release we will report key ESG Metrics on an ongoing
basis. Afya’s engagement on these topics is generating a
significant impact on society which makes our team very proud and
even more committed to our values and strategy.
2. Key Events in the
Quarter:
- Authorization to
operate the undergraduate medicine courses in Santa Inês, in the
State of Maranhão, starting October 2, 2020 and in Cruzeiro do Sul,
in the State of Acre, starting December 30, 2020, under the Mais
Médicos II program, adding 100 medical seats.
- Closing of
MedPhone acquisition - MedPhone is a clinical decision software and
medical information guide app in Brazil that helps physicians,
medical students and other healthcare professionals to make faster
and more accurate decisions on a daily basis.
- Closing of FCMPB
acquisition, a medical school in the state of Paraíba, adding 157
medical seats and 861 students to the student base and of FESAR, a
medical school located in the state of Pará, adding 120 medical
seats and 359 students in the beginning of November, 2020.
- Entrance into a
purchase agreement in October, 2020 for the acquisition of
UNIFIPMoc and Fip Guanambi, in the states of Minas
Gerais and Bahia, respectively, adding another 160
medical seats.
- Authorization of
a share buyback program for up to 1,015,844 outstanding Class A
common shares to be purchased in the open market, based on
prevailing market prices, or in privately negotiated transactions,
over a period beginning on December 24, 2020 continuing until the
earlier of the completion of the repurchase or December 31, 2021,
depending upon market conditions.
3. Subsequent Events in
the Quarter
- Closing of the
iClinic acquisition in January, 2021 – a leading practice
management software for physicians in Brazil, expanding Afya’s
end-to-end digital health services.
- Medicinae
acquisition in March 2021 – a unique financial platform that allows
healthcare professionals throughout Brazil to manage receivables in
an efficient and scalable way using FIDC (Receivables Investment
Fund). Medicinae alleviates a number of challenges in the
healthcare payments industry, as it reduces long payment cycles for
professionals and consolidates financial information, improving the
consumer financial experience.
- Medical Harbour
acquisition in April, 2021 – Medical Harbour offers Educational
Health and Medical Imaging Solutions through an interactive
platform for anatomical study, 3D virtual dissection and analysis
of medical images, which allow the exploration, and knowledge of
human anatomy with digital resources.
4. Second Half 2020
Guidance Achievement
Taking into account the challenges brought about
by the Coronavirus outbreak, the Company’s financial results
reaffirmed the resiliency of its business model. Net Revenue of R$
642 million was R$ 2 million above the top end of the guidance
range, while the EBITDA margin was within the guidance range.
|
|
Guidance for 2H2020 |
Actual 2H2020 |
Net Revenue (1) (2) (3) |
|
R$ 600 mn ≤ ∆ ≤ R$ 640 mn |
R$ 641.9 mn |
Adjusted EBITDA Margin |
|
45.5% ≤ ∆ ≥ 47.0% |
45.9% |
|
|
|
|
(1) Includes PEBMED starting on July 20, 2020. |
(2) Includes R$ 14.4 million of Net Revenue related to the 1H20
that was not recognized due to the postponement of practical
classes during the pandemic. |
(3) Excludes any acquisition that may have been concluded after the
issuance of the guidance. Thus, does not include FCMPB, FESAR and
MedPhone |
5. First Half 2021
GuidanceThe Company is introducing guidance for 1H21 which
takes into account the successfully concluded acceptances of new
medicine students, ensuring 100% occupancy for the first half of
2021 in all of its medical schools. Brazil is still facing
uncertain times due COVID-19 which could have some effect on the
business which is unpredictable at this time.
Considering the above factors, the guidance for
1H21 is defined in the following table:
Guidance for 1H21 |
Important considerations |
Net Revenue is expected to be between R$740 million – R$780
million |
- Includes Mais Médicos schools in Santa Inês and Cruzeiro do Sul
starting on January 1, 2021.
|
- Includes iClinic starting on January 21, 2021.
|
- Excludes any acquisition that may be concluded after the
issuance of the guidance. For example, it does not include
UNIFIPMOC, which 2020 estimated Net Revenue was R$109 million.
|
Adjusted EBITDA Margin is expected to be between 46.0%-48.0% |
- Includes Mais Médicos schools in Santa Inês and Cruzeiro do Sul
starting on January 1, 2021.
|
- Includes iClinic starting on January 21, 2021.
|
- Excludes any acquisition that may be concluded after the
issuance of the guidance. For instance does not include
UNIFIPMOC.
|
- Includes the impact of the adoption of IFRS 16.
|
The guidance above represents up to 42.7% YoY
growth in terms of Net Revenue and up to 44.7% YoY growth in terms
of Adjusted EBITDA, both at the high end of the guidance range.
This guidance reflects the embedded growth through the medical
school seats and average tuition maturation, along with a
successful acquisition strategy and the strength of the Company’s
digital platform.
6. Overview of 2020
& 4Q20
Operational Review
Afya is the only company offering technological
solutions to support physicians across every stage of the medical
career, from undergraduate students in its medical school years
through medical residency preparatory courses, medical
specialization programs and continuing medical education. With the
acquisition of PEBMED Afya entered into digital health services,
providing content and clinical decision applications.
The Company operates two distinct business
units. The first (Business Unit 1 or BU1), is
comprised of Undergraduate – medical schools, other healthcare
programs and ex-health degrees. Revenue is generated from the
monthly tuition fees the Company charges students enrolled in the
undergraduate programs. The Company also offers Residency
Preparatory, Specialization Programs and Digital Health Services
(Business Unit 2 or BU2). Revenue is comprised of
fees from these programs and other revenues from digital services
offered.
Key Revenue Drivers –
BU1 |
|
|
|
|
|
|
|
Table 2: Key Revenue Drivers |
Twelve months ended December 31, |
|
2020 |
2019 |
% Chg |
Business Unit 1: Educational Services Segment
(1) |
|
|
|
MEDICAL SCHOOL |
|
|
|
Approved Seats (2) |
2,143 |
1,572 |
36.3 |
% |
Operating Seats |
1,893 |
1,222 |
54.9 |
% |
Total Students |
11,030 |
6,597 |
67.2 |
% |
Total Students (ex- Acquisitions)* |
7,854 |
5,603 |
40.2 |
% |
Tuition Fees (ex- Acquisitions - R$MM) |
751,627 |
491,556 |
52.9 |
% |
Tuition Fees (Total - R$MM) |
910,966 |
550,208 |
65.6 |
% |
Medical School Avg. Ticket (ex- Acquisitions* -
R$/month) |
7,975 |
7,311 |
9.1 |
% |
UNDERGRADUATE HEALTH SCIENCE |
|
|
|
Total Students |
10,325 |
6,494 |
59.0 |
% |
Total Students (ex- Acquisitions)* |
5,882 |
6,494 |
-9.4 |
% |
Tuition Fees (ex- Acquisitions* - R$MM) |
101,558 |
98,488 |
3.1 |
% |
Tuition Fees (Total - R$MM) |
152,539 |
98,488 |
54.9 |
% |
OTHER UNDERGRADUATE |
|
|
|
Total Students |
14,851 |
10,878 |
36.5 |
% |
Total Students (ex- Acquisitions)* |
8,603 |
10,878 |
-20.9 |
% |
Tuition Fees (ex- Acquisitions* - R$MM) |
110,952 |
145,631 |
-23.8 |
% |
Tuition Fees (Total - R$MM) |
172,961 |
145,631 |
18.8 |
% |
|
|
|
|
* In 2019 acquisitions includes FASA and IPEC. In 2020 acquisitions
includes UniRedentor, UniSL, PEBMED, FCMPB, MedPhone, FESAR and
ITPAC Santa Inês. |
1. UniRedentor average tuition fee for medical school in 9M2020 was
R$ 9,625 and for UniSL was R$7,010. |
2. This number does not include FCMPB and FESAR that had the
closing of the operations in November, 2020 and contribute 277
seats to Afya. |
|
|
|
|
|
|
|
|
Key Revenue Drivers – BU2 |
|
|
|
|
|
|
|
Table 2: Key Revenue Drivers |
Twelve months ended December 31, |
|
2020 |
2019 |
% Chg |
Business Unit 2: Prep Courses & CME, Medical
Specialization and Digital Health Services |
|
|
Prep Courses |
|
|
|
Active Paying Students |
|
|
|
Prep Courses & CME - B2C |
11,316 |
9,577 |
18.2 |
% |
Prep Courses & CME - B2B |
1,723 |
1,182 |
45.8 |
% |
Medical Specialization & Others |
|
|
|
Medical Specialization & Others |
4,181 |
1,588 |
163.3 |
% |
Medical Specialization & Others (ex-UniRedentor) |
1,571 |
1,588 |
-1.1 |
% |
Digital Health Services - Clinical Decision
Software |
|
|
|
WhiteBook Active Subscribers |
106,977 |
81,874 |
30.7 |
% |
Revenue from courses (ex- UniRedentor and PEBMED - R$MM)
(3) |
186,642 |
100,750 |
85.3 |
% |
Revenue from courses (Total - R$MM) (3) |
200,349 |
100,750 |
98.9 |
% |
|
|
|
|
* Acquisitions includes UniRedentor, UniSL, PEBMED, FCMPB,
MedPhone, FESAR and ITPAC Santa Inês. |
|
3. As Medcel and IPEMED were acquired on March 31, 2019 and on
May 9, 2019 respectively, revenue from courses for BU2 were not
accounted for in 1Q19. The number of students is disclosed to
contribute with investors analysis. |
Key Operational Drivers –
BU2
Monthly Active Users (MaU) represents the number
of unique individuals that consumed Afya’s digital content in the
last 30 days of a specific period. Total monthly active users were
162,512 in WhiteBook, 1.5% lower than 3Q20.
Considering only the MaU of Medcel, the user
base decreased 20.0% due to COVID related courses that were offered
in 2Q20, which temporarily inflated MaU in that quarter. Afya’s
offers to its MaU a significant amount of learning assets,
comprised of e-books, videos, podcasts and question/answer
documents.
Table 3: Key Operational Drivers for BU2 |
2020 |
|
4Q20 |
3Q20 |
% Chg |
|
2Q20 |
1Q20 |
Total Monthly Active Users (MaU) - Medcel |
14,658 |
18,322 |
-20.0 |
% |
|
20,420 |
16,008 |
Total Monthly Active Users (MaU) - WhiteBook |
162,512 |
165,035 |
-1.5 |
% |
|
- |
- |
Seasonality
Afya’s two businesses are impacted by
seasonality but at different time periods. The first is associated
with the concentration of prep course revenues in the first and
fourth quarters of each year, when new content (books and e-books)
is delivered and the majority of the revenues are recognized. The
second is associated with the maturation of several medical
schools, which leads to a higher enrollment base in the second half
of each year. As a result, in a typical year, the first quarter is
normally the strongest. The fourth quarter is typically the second
strongest, followed by the third and second quarters, respectively.
Finally, the second half of the year is normally stronger than the
first half.
Revenue
Total Net Revenue for fourth quarter 2020 was
R$345.3 million, an increase of 56.3% over the same period of prior
year, due to maturation of medical seats, expansion of Afya Digital
and consolidating acquisitions. Adjusted Net Revenue in 4Q20, which
includes the impact of R$2.6 million due to net temporary discounts
in tuition fees granted by state decrees and individual and
collective legal proceedings related to COVID 19, was R$347.9
million. Excluding acquisitions (UniRedentor, UniSL, PEBMED, FCMPB,
MedPhone, FESAR and ITPAC Santa Inês), Adjusted Net Revenue in the
fourth quarter increased 10.7% YoY to R$244.4 million.
For the twelve-months ended December 31, 2020,
Total Net Revenue was R$1,201.2 million, up 60.0% over the same
period of last year. Full year Adjusted Net Revenue was also
R$1,207.7 million. Excluding acquisitions (UniRedentor, UniSL,
PEBMED, FCMPB, MedPhone, FESAR and ITPAC Santa Inês), Adjusted Net
Revenue in the twelve-months ended December 31, 2020 increased
27.6% YoY, reaching R$957.8 million.
The Company anticipated the enrollment process
to the 1H2020, thus creating a strong base of students. This
strategy ensured a 100% occupancy of medical seats and resulted in
stronger revenue growth in the first semester over the second
semester.
Table 4: Revenue & Revenue Mix |
(in thousands of R$) |
For the three months period ended December
31, |
|
For the Twelve months period ended December
31, |
|
2020 |
2020 Ex Acquisitions* |
2019 |
% Chg |
% Chg Ex Acquisitions |
|
2020 |
2020 Ex Acquisitions* |
2019 |
% Chg |
% Chg Ex Acquisitions |
Net Revenue Mix |
|
|
|
|
|
|
|
|
|
|
|
Business Unit-1 |
284,193 |
193,722 |
176,129 |
61.4% |
10.0% |
|
1,002,461 |
852,301 |
653,760 |
53.3% |
30.4% |
Business Unit-2 |
61,073 |
50,073 |
44,717 |
36.6% |
12.0% |
|
200,349 |
102,538 |
100,750 |
98.9% |
1.8% |
Inter-segment transactions |
- |
- |
- |
- |
- |
|
- 1,619 |
|
- 3,880 |
-58.3% |
- |
Total Reported Net Revenue |
345,266 |
243,795 |
220,846 |
56.3% |
10.4% |
|
1,201,191 |
954,839 |
750,630 |
60.0% |
27.2% |
Total Adjusted Net Revenue ¹ |
347,896 |
244,405 |
220,846 |
57.5% |
10.7% |
|
1,207,735 |
957,790 |
750,630 |
60.9% |
27.6% |
Total Pro Forma Adjusted Net Revenue² |
347,896 |
244,405 |
220,846 |
57.5% |
10.7% |
|
1,207,735 |
957,790 |
829,731 |
45.6% |
15.4% |
|
|
|
|
|
|
|
|
|
|
|
|
* Acquisitions includes UniRedentor, UniSL, PEBMED, FCMPB,
MedPhone, FESAR and ITPAC Santa Inês. |
1. Includes mandatory discounts in tuition fees granted by state
decrees and individual and collective legal proceedings due
COVID-19. |
2. Includes the pro forma results of Medcel, IPEMED and FASA, as if
the acquisitions had been consummated on January 1, 2019. |
Adjusted EBITDA
Adjusted EBITDA in the three-months ended
December 31, 2020 increased 51.3% to R$155.0 million, up from
R$102.5 million in the same period of the prior year. Adjusted
EBITDA Margin of 44.6% decreased from 46.4% due to the postponement
of Medcel’s revenue recognition caused by delays in book shipments
and change in the methodology of allowance for doubtful accounts in
4Q19.
Excluding the consolidation of acquisitions
(UniRedentor, UniSL, PEBMED, FCMPB, MedPhone, FESAR and ITPAC Santa
Inês), Adjusted EBITDA in the three-months ended December 31, 2020
increased 8.1% YoY to R$110.8 million from R$102.5 million while
Adjusted EBITDA Margin decreased 110 basis points to 45.3%.
For the twelve-months ended December 31, 2020,
Pro forma Adjusted EBITDA increased 55.7% to R$563.1 million, from
R$361.6 million in the twelve-months ended December 31, 2019.
Adjusted EBITDA Margin of 46.6% was 300 basis points higher than
the same period of the prior year, benefitting from the synergies
extracted from the successful integration of acquisitions and
medical seats and tickets maturation.
For the twelve-months ended December 31, 2020,
Pro forma Adjusted EBITDA excluding acquisitions (UniRedentor,
UniSL, PEBMED, FCMPB, MedPhone, FESAR and ITPAC Santa Inês)
increased 29.2% YoY to R$467.2 million up from R$361.6 million
while Pro forma Adjusted EBITDA Margin increased 520 basis points,
to 48.8% from 43.6%, mainly due to operational leverage and
synergies obtained from recent acquisitions.
Table 5: Adjusted EBITDA |
(in thousands of R$) |
For the three months period ended December
31, |
|
For the twelve months period ended December
31, |
|
2020 |
2020 Ex Acquisitions* |
2019 |
% Chg |
% Chg Ex Acquisitions |
|
2020 |
2020 Ex Acquisitions* |
2019 |
% Chg |
% Chg Ex Acquisitions |
Adjusted EBITDA |
155,048 |
110,746 |
102,491 |
51.3% |
8.1% |
|
563,113 |
467,235 |
333,436 |
68.9% |
40.1% |
% Margin |
44.6% |
45.3% |
46.4% |
-180 bps |
-110 bps |
|
46.6% |
48.8% |
44.4% |
220 bps |
440 bps |
Proforma Adjusted EBITDA¹ |
155,048 |
110,746 |
102,491 |
51.3% |
8.1% |
|
563,113 |
467,235 |
361,622 |
55.7% |
29.2% |
% Margin |
44.6% |
45.3% |
46.4% |
-180 bps |
-110 bps |
|
46.6% |
48.8% |
43.6% |
300 bps |
520 bps |
|
|
|
|
|
|
|
|
|
|
|
|
* Acquisitions includes UniRedentor, UniSL, PEBMED, FCMPB,
MedPhone, FESAR and ITPAC Santa Inês. |
|
|
|
1. Includes the pro forma results of Medcel, IPEMED and FASA, as if
the acquisitions had been consummated on January 1, 2019. |
Adjusted Net Income
Adjusted Net Income for the fourth quarter of
2020 was R$83.1 million, up 14.6% over the same period of the prior
year and reflects lower financial results, due to the 8.0% exchange
rate depreciation (US Dollar versus Brazilian Real) in the period,
the increase on loan agreements and debts with selling shareholders
and the increase of R$9.0 million in non-recurring expenses.
For the twelve-months ended December 31, 2020,
the Company reported Adjusted Net Income of R$390.9 million,
compared to an Adjusted Net Income of R$226.9 million in the
twelve-months ended December 31, 2019, an increase of 72.2%, mainly
due to revenue contribution, synergies captured and margin
expansion from the consolidation of acquisitions as well as organic
growth. Earnings per share (EPS) was up 55.2% year over year,
reaching R$ 3.15.
(in thousands of R$) |
|
|
|
|
|
|
|
|
For the three months period ended December
31, |
|
For the twelve months period ended December
31, |
|
2020 |
2019 |
% Chg |
|
2020 |
2019 |
% Chg |
Net income |
60,856 |
52,976 |
14.9% |
|
307,987 |
172,762 |
78.3% |
Amortization of customer relationships and trademark (1) |
14,299 |
11,303 |
26.5% |
|
50,312 |
36,077 |
39.5% |
Share-based compensation |
7,961 |
8,250 |
-3.5% |
|
32,610 |
18,114 |
80.0% |
Adjusted Net Income |
83,116 |
72,529 |
14.6% |
|
390,909 |
226,953 |
72.2% |
|
|
|
|
|
|
|
|
Basic earnings per share (R$) |
|
|
|
|
3.15 |
2.03 |
55.2% |
|
|
|
|
|
|
|
|
(1) Consists of amortization of customer relationships and
trademark recorded under business combinations. |
Cash and Debt Position
Cash and cash equivalents, including restricted
cash, at December 31, 2020 were R$1.0 billion, in line with the
cash position in September 30, 2020.
For the twelve-month period ended December 31,
2020, Afya reported an Adjusted Cash Flow from Operations of
R$390.9 million up from R$307.7 million in same period of previous
year, a 27.0% year-over-year increase.
Operating Cash Conversion Ratio for the
twelve-month period ended December 31, 2020 was 75.7% compared with
99.7% in same period of the previous year. This decrease was mainly
due to: (a) consolidation of Medcel, as its results negatively
affect cash conversion in the first and fourth quarters, because
prep courses revenues are recognized mainly in the first and fourth
quarters of each year; and (b) students renegotiation of overdue
monthly installments due to COVID-19 crisis which increased
accounts receivable in the period.
Table 6: Operating Cash Conversion Ratio
Reconciliation |
For the twelve months period ended December
31, |
(in thousands of R$) |
Considering the adoption of IFRS 16 |
|
2020 |
2019 |
% Chg |
(a) Cash flow from operations |
371,507 |
299,216 |
24.2% |
(b) Income taxes paid |
19,374 |
8,506 |
127.8% |
(c) = (a) + (b) Adjusted cash flow from
operations |
390,881 |
307,722 |
27.0% |
|
|
|
|
(d) Adjusted EBITDA |
563,113 |
333,436 |
68.9% |
(e) Non-recurring expenses: |
|
|
|
- Integration of new companies (1) |
9,765 |
6,301 |
55.0% |
- M&A advisory and due diligence (2) |
6,161 |
2,752 |
123.9% |
- Expansion projects (3) |
18,134 |
3,685 |
392.1% |
- Restructuring Expenses (4) |
5,943 |
12,139 |
-51.0% |
- Mandatory Discounts in Tuition Fees (5) |
6,544 |
- |
n.a. |
(f) = (d) - (e) Adjusted EBITDA ex- non-recurring
expenses |
516,565 |
308,559 |
67.4% |
(g) = (a) / (f) Operating cash conversion
ratio |
75.7% |
99.7% |
-2400 bps |
(1) Consists of expenses related to the integration of newly
acquired companies. |
|
|
(2) Consists of expenses related to professional and consultant
fees in connection with due diligence services for M&A
transactions. |
(3) Consists of expenses related to professional and consultant
fees in connection with the opening of new campuses. |
(4) Consists of expenses related to the employee redundancies in
connection with the organizational restructuring of acquired
companies. |
(5) Consists of mandatory discounts in tuition fees granted by
state decrees and individual and collective legal proceedings due
COVID-19 on site classes restriction. |
On December 31, 2020, net debt totaled R$166.9
million, compared with a net cash position of R$582.6 million on
December 31, 2019, mainly due to acquisitions payments.
Table 7: Cash and Debt Position |
For the twelve months period ended December
31, |
(in thousands of R$) |
|
|
|
|
2020 |
2019 |
% Chg |
(+) Cash and Cash Equivalents |
1,045,042 |
943,209 |
10.8% |
Cash and Bank Deposits |
57,729 |
13,092 |
340.9% |
Cash Equivalents |
987,313 |
930,117 |
6.1% |
(-) Loans and Financing |
617,485 |
60,357 |
923.1% |
Current |
107,162 |
53,607 |
99.9% |
Non-Current |
510,323 |
6,750 |
7460.3% |
(-) Accounts Payable to Selling Shareholders |
518,240 |
300,237 |
72.6% |
Current |
188,420 |
131,883 |
42.9% |
Non-Current |
329,820 |
168,354 |
95.9% |
(-) Other Short and Long Term Obligations |
76,181 |
0 |
N/A |
(=) Net Debt (Cash) excluding IFRS 16 |
166,864 |
-582,615 |
- |
(-) Lease Liabilities |
447,703 |
284,515 |
57.4% |
Current |
61,976 |
22,693 |
173.1% |
Non-Current |
385,727 |
261,822 |
47.3% |
Net Debt (Cash) with IFRS 16 |
614,567 |
-298,100 |
- |
ESG Metrics
Education and health, pillars for Afya's
business, are also crucial issues for individuals’ well-being and
socio-economic development. In turn, Afya, which has schools
distributed nationwide is able to have positive impacts for local
communities.
The Company operates in many regions that do not
have sufficient numbers of physicians to serve the population, the
healthcare system is in need of investments and the population does
not have access to quality health services. With Afya’s regional
presence, the Company is able to attract medical and health
professionals to remote regions, to make investment in the local
healthcare system, along with providing free consultations for low
income populations.
Afya ensures that its human resource policies
encompass social inclusion, employees’ well-being, gender equality
and people development. More than half of Afya’s employees are
female, 55% of the management positions are held by women and there
are two women on the board of directors, accounting for 18% of the
11 total members. Additionally, the Company is committed to
supporting the disabled community and guarantees that 3% of its
hires fall into this category.
With respect to the environment the Company is
undertaking a project to install solar panels in all of its
campuses which will generate all the energy needed by Afya. The
Company currently has 4 campuses operating with solar panels and 8
campuses are in the process of implementation.
ESG commitment is an important part of Afya’s
strategy and permeates the Company’s core values. Afya has been
advancing year after year on its core pillars and, going forward,
ESG metrics will be disclosed in the Company’s quarterly financial
results.
Table 8: ESG Metrics |
2020 |
2019 |
# |
Governance and Employee Management |
|
|
1 |
Number of employees |
6,100 |
3,369 |
2 |
Percentage of female employees |
55.0% |
57.0% |
3 |
Percentage of female employees in the board of directors |
18% |
22% |
4 |
Percentage of independent member in the board of directors |
36% |
22% |
|
Environmental |
|
|
4 |
Total energy consumption (kWh) |
6,428,382 |
5,928,450 |
4.1 |
Consumption per campus |
257,135 |
395,230 |
5 |
% supplied by distribution companies |
87.4% |
96.2% |
6 |
% supplied by other sources |
12.6% |
3.8% |
7 |
Greenhouse gas emissions (tons) |
397 |
445 |
|
Social |
|
|
8 |
Number of free consultations offered by Afya students |
427,184 |
270,000 |
9 |
Number of physicians graduated in Afya's campuses |
12,691 |
8,306 |
10 |
Number of students with financing programs (FIES and PROUNI) |
4,999 |
2,808 |
11 |
% of the undergraduate students |
13.7% |
11.7% |
12 |
Hospital and clinics partnership |
432 |
60 |
7. Conference Call and
Webcast Information
When: April 9, 2021 at 11:00
a.m. ET.
Who: |
Mr. Virgilio Gibbon, Chief Executive OfficerMr. Luis André Blanco,
Chief Financial OfficerMs. Renata Costa Couto, Head of Investor
Relations |
Dial-in: Brazil: +55 11 4632 2237
or +55 11 4680 6788 or +55 11 4700 9668 or +55 21
3958 7888 or +55 11 4632 2236
United States: +1 929 205 6099 or +1 301 715 8592 or
+1 312 626 6799 or +1 669 900 6833 or +1 253 215 8782
or +1 346 248 7799
ID to webinar: 913 4980 5259
Other Numbers: https://afya.zoom.us/u/aeG5a381E
OR Webcast:
https://afya.zoom.us/j/91349805259 ID to webinar: 913 4980 5259
8. About Afya Limited
(Nasdaq: AFYA)
Afya is the leading medical education group in
Brazil based on number of medical school seats, delivering an
end-to-end physician-centric ecosystem that serves and empowers
students to be lifelong medical learners from the moment they
enroll as medical students through their medical residency
preparation, graduation program, and continuing medical education
activities. Afya also offers content and clinical decision
applications for healthcare professionals, through its products
WhiteBook, Nursebook and Portal PEBMED. For more information,
please visit www.afya.com.br.
9. Forward – Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, which statements involve substantial risks and
uncertainties. All statements other than statements of historical
fact, could be deemed forward looking, including risks and
uncertainties related to statements about our competition; our
ability to attract, upsell and retain students; our ability to
increase tuition prices and prep course fees; our ability to
anticipate and meet the evolving needs of student and teachers; our
ability to source and successfully integrate acquisitions; general
market, political, economic, and business conditions; and our
financial targets such as revenue, share count and IFRS and
non-IFRS financial measures including gross margin, operating
margin, net income (loss) per diluted share, and free cash flow.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain, such as statements about the
potential impacts of the COVID-19 pandemic on our business
operations, financial results and financial position and on the
Brazilian economy.
The Company undertakes no obligation to update
any forward-looking statements made in this press release to
reflect events or circumstances after the date of this press
release or to reflect new information or the occurrence of
unanticipated events, except as required by law. The achievement or
success of the matters covered by such forward-looking statements
involves known and unknown risks, uncertainties and assumptions. If
any such risks or uncertainties materialize or if any of the
assumptions prove incorrect, our results could differ materially
from the results expressed or implied by the forward-looking
statements we make. Readers should not rely upon forward-looking
statements as predictions of future events. Forward-looking
statements represent management’s beliefs and assumptions only as
of the date such statements are made. Further information on these
and other factors that could affect the Company’s financial results
is included in filings made with the United States Securities and
Exchange Commission (SEC) from time to time, including the section
titled “Risk Factors” in the most recent Rule 434(b) prospectus.
These documents are available on the SEC Filings section of the
investor relations section of our website at:
https://ir.afya.com.br/.
10. Non-GAAP Financial
Measures
To supplement the Company's consolidated
financial statements, which are prepared and presented in
accordance with International Financial Reporting Standards as
issued by the International Accounting Standards Board—IASB, Afya
uses Proforma Revenue, Adjusted EBITDA, Pro Forma Adjusted EBITDA,
Pro Forma Adjusted Net Income and Operating Cash Conversion Ratio
information for the convenience of investors, which are non-GAAP
financial measures. A non-GAAP financial measure is generally
defined as one that purpose to measure financial performance but
excludes or includes amounts that would not be so adjusted in the
most comparable GAAP measure.
Afya calculates Adjusted EBITDA as net income
plus/minus net financial result plus income taxes expense plus
depreciation and amortization plus interest received on late
payments of monthly tuition fees, plus share-based compensation
plus/minus income share associate plus/minus non-recurring
expenses. Pro Forma Adjusted EBITDA is calculated as pro forma net
income plus/minus pro forma net financial result plus pro forma
income taxes expense plus pro forma depreciation and amortization
plus pro forma interest received on late payments of monthly
tuition fees, plus pro forma share-based compensation plus/minus
pro forma income share associate plus/minus pro forma non-recurring
expenses. The calculation for Adjusted Net Income is net income
plus amortization of customer relationships and trademark, plus
shared based compensation. We calculate Operating Cash Conversion
Ratio as the cash flows from operations, adjusted with income taxes
paid divided by Adjusted EBITDA plus/minus non-recurring
expenses.
Management presents Adjusted EBITDA, Pro Forma
Adjusted EBITDA and Pro Forma Adjusted Net Income because it
believes these measures provide investors with a supplemental
measure of the financial performance of the core operations that
facilitates period-to-period comparisons on a consistent basis.
Afya also presents Operating Cash Conversion Ratio because it
believes this measure provides investors with a measure of how
efficiently the Company converts EBITDA into cash. The non-GAAP
financial measures described in this prospectus are not a
substitute for the IFRS measures of earnings. Additionally,
calculations of Adjusted EBITDA, Pro Forma Adjusted EBITDA, Pro
Forma Adjusted Net Income and Operating Cash Conversion Ratio may
be different from the calculations used by other companies,
including competitors in the education services industry, and
therefore, Afya’s measures may not be comparable to those of other
companies.
11. Unaudited
Consolidated Financial Information and Pro Forma Condensed
Consolidated Financial Information
These preliminary results are unaudited and are
based on management's initial review of operations for the fourth
quarter and year ended December 31, 2020 and remain subject to the
completion of the Company's customary annual closing and review
procedures by our external auditors as well the completion of the
first year attestation to management’s assessment of the
effectiveness of its internal control over financial reporting
(SOX). Final adjustments and other reclassification may arise
between the date hereof and the filing of the Company's Annual
Report on Form 20-F at the end of April.
The unaudited interim pro forma condensed
consolidated statement of income for the twelve ended December 31,
2019 is based on the historical unaudited interim consolidated
financial statements of each company, and gives effect of the
acquisition of Medcel, IPEMED and FASA by Afya Brazil as if it had
been consummated on January 1, 2019. Pro forma adjustments were
made to reflect the acquisition of Medcel, IPEMED and FASA by Afya
Brazil.
12. Investor Relations
Contact
Renata Couto, Head of Investor RelationsPhone: +55 31
3515.7564 | +55 31
98463.3341E-mail: renata.couto@afya.com.br
13. Financial
Tables
Consolidated statements of
income
For the full year ended December 31, 2020, 2019 and
2018
(In thousands of Brazilian Reais, except earnings per
share)
|
2020(Unaudited) |
2019 |
2018 |
|
|
|
|
Net revenue |
1,201,191 |
750,630 |
333,935 |
Cost of services |
(434,654) |
(308,853) |
(168,052) |
Gross
profit |
766,537 |
441,777 |
165,883 |
|
|
|
|
General and administrative expenses |
(402,855) |
(239,120) |
(70,034) |
Other income, net |
(347) |
2,594 |
599 |
|
|
|
|
Operating
income |
363,335 |
205,251 |
96,448 |
|
|
|
|
Finance income |
62,290 |
51,689 |
10,428 |
Finance expenses |
(98,269) |
(72,365) |
(8,154) |
Finance result |
(35,979) |
(20,676) |
2,274 |
|
|
|
|
Share of income of
associate |
7,698 |
2,362 |
- |
|
|
|
|
Income before income
taxes |
335,054 |
186,937 |
98,722 |
|
|
|
|
Income taxes expense |
(27,067) |
(14,175) |
(3,988) |
|
|
|
|
Net
income |
307,987 |
172,762 |
94,734 |
|
|
|
|
Other comprehensive income |
- |
- |
- |
Total comprehensive
income |
307,987 |
172,762 |
94,734 |
|
|
|
|
Income attributable to |
|
|
|
Equity holders of the parent |
292,075 |
153,916 |
86,353 |
Non-controlling interests |
15,912 |
18,846 |
8,381 |
|
307,987 |
172,762 |
94,734 |
Basic earnings per
share |
|
|
|
Per common share |
3.15 |
2.03 |
1.84 |
Diluted earnings per
share |
|
|
|
Per common share |
3.12 |
2.02 |
1.81 |
Consolidated balance sheets - For the full year ended
December 31, 2020 and 2019
(In thousands of Brazilian Reais)
|
2020(Unaudited) |
2019 |
Assets |
|
|
Current
assets |
|
|
Cash and cash equivalents |
1,045,042 |
943,209 |
Restricted cash |
- |
14,788 |
Trade receivables |
302,317 |
125,439 |
Inventories |
7,509 |
3,932 |
Recoverable taxes |
21,019 |
6,485 |
Other assets |
29,614 |
17,912 |
Total current assets |
1,405,501 |
1,111,765 |
|
|
|
Non-current
assets |
|
|
Restricted cash |
2,053 |
2,053 |
Trade receivables |
7,627 |
9,801 |
Other assets |
74,037 |
17,267 |
Property and equipment |
260,381 |
139,320 |
Investment in associate |
51,410 |
45,634 |
Right-of-use assets |
419,074 |
274,275 |
Intangible assets |
2,573,010 |
1,312,338 |
Total non-current assets |
3,387,592 |
1,800,688 |
|
|
|
Total
assets |
4,793,093 |
2,912,453 |
Liabilities |
|
|
Current
liabilities |
|
|
Trade payables |
35,743 |
17,628 |
Loans and financing |
107,162 |
53,607 |
Derivatives |
- |
757 |
Lease liabilities |
61,976 |
22,693 |
Accounts payable to selling shareholders |
188,420 |
131,883 |
Notes Payable |
10,503 |
- |
Advances from customers |
63,839 |
36,860 |
Labor and social obligations |
77,855 |
46,770 |
Taxes payable |
32,976 |
19,442 |
Income taxes payable |
4,574 |
3,213 |
Other liabilities |
6,331 |
376 |
Total current liabilities |
589,379 |
333,229 |
|
|
|
Non-current
liabilities |
|
|
Loans and financing |
510,323 |
6,750 |
Lease liabilities |
385,727 |
261,822 |
Accounts payable to selling shareholders |
329,820 |
168,354 |
Notes payable |
65,678 |
- |
Taxes payable |
21,425 |
21,304 |
Provision for legal proceedings |
53,139 |
5,269 |
Other liabilities |
3,822 |
1,999 |
Total non-current liabilities |
1,369,934 |
465,498 |
Total
liabilities |
1,959,313 |
798,727 |
|
|
|
Equity |
|
|
Share capital |
17 |
17 |
Additional paid-in capital |
2,323,488 |
1,931,047 |
Share-based compensation reserve |
50,724 |
18,114 |
Retained earnings |
407,991 |
115,916 |
Equity attributable to
equity holders of the parent |
2,782,220 |
2,065,094 |
Non-controlling interests |
51,560 |
48,632 |
Total
equity |
2,833,780 |
2,113,726 |
Total liabilities and
equity |
4,793,093 |
2,912,453 |
Consolidated statements of cash flow - For the full year
ended December 31, 2020, 2019 and 2018
(In thousands of Brazilian Reais)
|
2020(Unaudited) |
2019 |
2018 |
|
|
|
|
Operating
activities |
|
|
|
|
Income before
income taxes |
335,054 |
186,937 |
98,722 |
|
|
Adjustments to
reconcile income before income taxes |
|
|
|
|
|
|
Depreciation and amortization |
108,744 |
73,152 |
9,078 |
|
|
|
Disposals of property and
equipment |
- |
78 |
- |
|
|
|
Allowance for doubtful
accounts |
32,081 |
15,040 |
7,714 |
|
|
|
Share-based compensation
expense |
32,610 |
18,114 |
2,161 |
|
|
|
Net foreign exchange
differences |
4,613 |
(13,321) |
2,697 |
|
|
|
Net loss (gain) on
derivatives |
(20,739) |
1,780 |
(1,219) |
|
|
|
Accrued interest |
25,543 |
24,002 |
1,856 |
|
|
|
Accrued lease interest |
44,458 |
31,469 |
- |
|
|
|
Share of income of
associate |
(7,698) |
(2,362) |
- |
|
|
|
Provision for legal
proceedings |
5,354 |
(2,568) |
(344) |
|
|
|
Others |
- |
- |
(11) |
Changes in
assets and liabilities |
|
|
|
|
Trade
receivables |
(164,286) |
(35,556) |
(28,198) |
|
Inventories |
(3,110) |
(236) |
(593) |
|
Recoverable
taxes |
(13,709) |
(3,940) |
(63) |
|
Other assets |
(23,902) |
(7,403) |
(3,304) |
|
Trade
payables |
4,475 |
3,029 |
(1,528) |
|
Taxes
payables |
(552) |
4,940 |
(3,797) |
|
Advances from
customers |
(1,951) |
19,324 |
2,073 |
|
Labor and social
obligations |
11,125 |
6,124 |
(3,019) |
|
Other
liabilities |
22,771 |
(10,881) |
1,990 |
|
|
390,881 |
307,722 |
84,215 |
|
Income taxes
paid |
(19,374) |
(8,506) |
(3,897) |
|
Net cash
flows from operating activities |
371,507 |
299,216 |
80,318 |
|
|
|
|
|
|
|
Investing
activities |
|
|
|
|
Acquisition of
property and equipment |
(89,832) |
(56,964) |
(18,634) |
|
Acquisition of
intangibles assets |
(47,753) |
(64,745) |
(3,053) |
|
Restricted
cash |
14,788 |
7,530 |
(18,810) |
|
Payments of notes
payable |
(5,974) |
- |
- |
|
Acquisition of
subsidiaries, net of cash acquired |
(913,991) |
(241,568) |
(221,298) |
|
Loans to related
parties |
- |
1,598 |
(594) |
|
Net cash
flows used in investing activities |
(1,042,762) |
(354,149) |
(262,389) |
Financing
activities |
|
|
|
|
Issuance of loans
and financing |
605,041 |
7,383 |
74,980 |
|
Payments of loans
and financing |
(155,090) |
(75,093) |
(6,492) |
|
Payments of lease
liabilities |
(55,455) |
(39,779) |
- |
|
Related parties
loans |
- |
- |
(106) |
|
Capital
increase |
5,444 |
167,628 |
156,304 |
|
Dividends paid to
non-controlling interests |
(12,984) |
(51,812) |
(5,845) |
|
Proceeds from
initial public offering |
389,170 |
992,778 |
- |
|
Share issuance
costs |
(19,704) |
(79,670) |
- |
|
Net cash
flows from (used in) financing activities |
756,422 |
921,435 |
218,841 |
|
Net foreign
exchange differences |
16,666 |
14,447 |
- |
|
Net
increase in cash and cash equivalents |
101,833 |
880,949 |
36,770 |
|
Cash and cash
equivalents at the beginning of the year |
943,209 |
62,260 |
25,490 |
|
Cash and cash
equivalents at the end of the year |
1,045,042 |
943,209 |
62,260 |
Reconciliation between Net Income and
Adjusted EBITDA, Pro Forma Adjusted EBITDA
Reconciliation between Adjusted EBITDA and Net Income;
Proforma Adjusted EBITDA |
(in thousands of R$) |
|
|
|
|
|
|
|
|
For the three months period ended December
31, |
|
For the twelve months period ended December
31, |
|
2020 |
2019 |
% Chg |
|
2020 |
2019 |
% Chg |
Net income |
60,856 |
52,976 |
14.9% |
|
307,987 |
172,762 |
78.3% |
Net financial result |
26,337 |
3,602 |
631.2% |
|
35,979 |
20,676 |
74.0% |
Income taxes expense |
9,979 |
4,473 |
123.1% |
|
27,067 |
14,175 |
90.9% |
Depreciation and amortization |
31,015 |
22,449 |
38.2% |
|
108,744 |
73,152 |
48.7% |
Interest received (1) |
2,407 |
1,952 |
23.3% |
|
11,876 |
9,680 |
22.7% |
Income share associate |
-1,305 |
0 |
n.a. |
|
-7,698 |
0 |
n.a. |
Share-based compensation |
7,961 |
8,250 |
-3.5% |
|
32,610 |
18,114 |
80.0% |
Non-recurring expenses: |
17,798 |
8,789 |
102.5% |
|
46,548 |
24,877 |
87.1% |
- Integration of new companies (2) |
1,809 |
1,814 |
-0.3% |
|
9,765 |
6,301 |
55.0% |
- M&A advisory and due diligence (3) |
1,205 |
1,226 |
-1.7% |
|
6,161 |
2,752 |
123.9% |
- Expansion projects (4) |
10,964 |
2,162 |
407.1% |
|
18,134 |
3,685 |
392.1% |
- Restructuring expenses (5) |
1,190 |
3,587 |
-66.8% |
|
5,943 |
12,139 |
-51.0% |
- Mandatory Discounts in Tuition Fees (6) |
2,630 |
0 |
n.a. |
|
6,544 |
0 |
n.a. |
Adjusted EBITDA |
155,048 |
102,491 |
51.3% |
|
563,113 |
333,436 |
68.9% |
Adjusted EBITDA Margin |
44.6% |
46.4% |
-180 bps |
|
46.6% |
44.4% |
220 bps |
Pro Forma Adjusted EBITDA |
155,048 |
102,491 |
51.3% |
|
563,113 |
361,622 |
55.7% |
Pro Forma Adjusted EBITDA Margin |
44.6% |
46.4% |
-180 bps |
|
46.6% |
43.6% |
300 bps |
|
|
|
|
|
|
|
|
(1) Represents the interest received on late payments of monthly
tuition fees. |
(2) Consists of expenses related to the integration of newly
acquired companies. |
(3) Consists of expenses related to professional and consultant
fees in connection with due diligence services for our M&A
transactions. |
(4) Consists of expenses related to professional and consultant
fees in connection with the opening of new campuses. |
(5) Consists of expenses related to the employee redundancies in
connection with the organizational restructuring of our acquired
companies. |
(6) Consists of mandatory discounts in tuition fees granted by
state decrees and individual and collective legal proceedings due
COVID-19 on site classes restriction. |
Afya (NASDAQ:AFYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Afya (NASDAQ:AFYA)
Historical Stock Chart
From Apr 2023 to Apr 2024